Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.

导出 LinkOut

翻译打印收藏纠错

作者： Fabian,Frontzek ^[1] ; Marita,Ziepert ^[2] ; Maike,Nickelsen ^[3] ; Bettina,Altmann ^[2] ; Bertram,Glass ^[4] ; Mathias,Haenel ^[5] ; Lorenz,Truemper ^[6] ; Gerhard,Held ^[7] ; Martin,Bentz ^[8] ; Peter,Borchmann ^[9] ; Martin,Dreyling ^[10] ; Andreas,Viardot ^[11] ; Frank P,Kroschinsky ^[12] ; Bernd,Metzner ^[13] ; Annette M,Staiger ^[14] ; Heike,Horn ^[14] ; German,Ott ^[14] ; Andreas,Rosenwald ^[15] ; Markus,Loeffler ^[2] ; Georg,Lenz ^[1] ; Norbert,Schmitz ^[16]

作者单位： Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany. ^[1] Institute for Medical Informatics, Statistics, and Epidemiology, University Leipzig, Leipzig, Germany. ^[2] Onkologie Lerchenfeld, Hamburg, Germany. ^[3] Clinic for Haematology, Oncology, Tumour Immunology, and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany. ^[4] Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany. ^[5] Haematology and Medical Oncology, Georg August University, Göttingen, Germany. ^[6] Department for Haematology and Oncology, Westpfalz-Klnikum Kaiserslautern, Kaiserslautern, Germany. ^[7] Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany. ^[8] Department I of Internal Medicine, University of Cologne, Cologne, Germany. ^[9] Department of Medicine III, Ludwig Maximilians Universität Hospital, Munich, Germany. ^[10] Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. ^[11] Department of Medicine I, University Hospital Dresden, Dresden, Germany. ^[12] Department of Internal Medicine, Oncology, and Haematology, University Hospital Klinikum Oldenburg, Oldenburg, Germany. ^[13] Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, University of Tübingen, Stuttgart, Germany; Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany. ^[14] Institute of Pathology, University of Würzburg, Würzburg, Germany. ^[15] Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany. Electronic address: norbert.schmitz@ukmuenster.de. ^[16]

主题词成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);中枢神经系统疾病(Central Nervous System Diseases);依托泊甙(Etoposide);女(雌)性(Female);随访研究(Follow-Up Studies);德国(Germany);造血干细胞移植(Hematopoietic Stem Cell Transplantation);人类(Humans);意向治疗分析(Intention to Treat Analysis);淋巴瘤, B细胞(Lymphoma, B-Cell);男(雄)性(Male);中年人(Middle Aged);泼尼松龙(Prednisolone);安全(Safety);拓扑异构酶II抑制剂(Topoisomerase II Inhibitors);移植, 自体(Transplantation, Autologous);治疗结果(Treatment Outcome);长春新碱(Vincristine)

DOI 10.1016/S2352-3026(21)00022-3

PMID 33667420

发布时间 2021-04-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The Lancet. Haematology

2021年8卷4期

e267-e277页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.

The Lancet. Haematology

相似文献

The Lancet. Haematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.

The Lancet. Haematology

相似文献

The Lancet. Haematology

相关期刊

检索历史清除